| Field | Specification |
|---|---|
| Organism | |
| Applications | |
| Tissue | |
| Disease | Normal tissue |
| Growth properties | |
| Biosafety level | |
| Product format | Frozen |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Overview
Human CD19+ B Cells are human frozen primary cells from blood used for B-cell activation, differentiation, and humoral immune signaling studies. These cells display suspension, round growth characteristics.
Key elements and design rationale
- Biological source: Human (H. sapiens)
- Tissue origin: Blood
- Growth properties: Suspension, round
- Format: Frozen
- Reported expression/markers: CD19+
- Donor history: Normal tissue
- Biosafety level: II
Primary B cells are used to study activation, antigen-dependent signaling, differentiation-associated programs, and interactions with T cells or innate immune stimuli.
Research relevance and current trends
- Studies often examine activation-state changes, proliferation, and cytokine or antibody-associated signaling readouts.
- Primary B-cell preparations support donor-comparison workflows and immune subset analysis.
- Co-culture systems are frequently used to investigate helper-cell or innate signaling effects on B-cell phenotype.
Common research applications
- Measure activation markers and signaling changes after defined stimulation.
- Use in donor-comparison or immune subset studies requiring primary-cell context.
- Evaluate co-culture-dependent changes in B-cell phenotype and function.
Product-specific data supplied for this listing
- Growth Conditions: PriGrow X Series Medium (TM4123) + 1% Penicillin/Streptomycin Solution (G255), 37.0°C, 5% CO₂.
- Warranty: abm warrants that cell lines shall be viable upon initiation of culture for a period of thirty (30) days after shipment and that they shall meet the specifications on the applicable abm Material Product Information sheet, certificate of analysis, and/or catalog description. Such thirty (30) day period is referred to herein as the "Warranty Period”.
Notes for experimental interpretation
- Primary cells can show donor-dependent and passage-dependent variation, so morphology, growth rate, and marker expression should be interpreted in the context of the specific lot and culture history.
- Attachment matrix, medium formulation, and gas conditions can materially influence phenotype maintenance and experimental readouts; use the recommended culture system where possible.
- Cryopreserved recovery conditions matter for viability and downstream behavior. We recommend using serum-free CryoGuard™ Freezing Media (TM078).
- Marker panels should be interpreted together with morphology and functional readouts rather than as a standalone identity measure.
- Thaw cells quickly in a 37°C water bath while agitating gently (maximum 2 minutes). The vial cap should be kept above the water level to minimize the risk of contamination.
- Decontaminate the vial by spraying and wiping the exterior of the vial with 70% ethanol. From this point onwards, all operations should be strictly carried out inside a biological safety cabinet using aseptic conditions.
- Transfer the cell suspension into a 15ml sterile conical tube containing 5ml of pre-warmed, complete growth media. Centrifuge cells at 125xg for 5-7 minutes.
- Aspirate the supernatant without disturbing the cell pellet. Re-suspend the cell pellet in the recommended pre-warmed, complete growth media and dispense into a T25 culture flask.
- Incubate the cells at the recommended conditions.
- Simply add fresh complete media directly to the culture. Do not allow cell density to exceed 1x10⁶ cells/ml.
- Alternatively, replace complete growth media by centrifugation and re-suspend the cell pellet in fresh complete media, and add appropriate aliquots of the cell suspension to new culture vessels, as desired.
- Incubate the cells at the recommended conditions.
Cell line sourcing and selection (species, tissue, and disease model matching) · Stable cell line engineering (overexpression, knockdown, knockout via CRISPR/Cas9, shRNA, sgRNA) · Reporter gene integration (GFP, RFP, luciferase, fluorescent/bioluminescent constructs) · Genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles) · Inducible expression systems (Tet-On/Off and regulatable constructs) · Drug resistance marker selection (puromycin, G418, hygromycin, and others) · Custom growth and media optimisation for specific assay requirements · Scale-up production for high-throughput screening campaigns · Authentication and QC services (STR profiling, mycoplasma testing, viability assessment). Talk to a Scientist or contact support@biohippo.com.
